Quantcast

Macrocyclics introduces new offices in Asia and Europe

July 7, 2014

DALLAS, July 7, 2014 /PRNewswire/ — Macrocyclics, Inc. (an AREVA Med company) announced today the launch of new offices located in China, Japan, South Korea, and France. The production laboratory remains based in Dallas, Texas, USA; however, Asian and French customers will now have a local contact for placing orders and obtaining technical information about all products and services available from Macrocyclics, and the ability to communicate in their own language as well as English.

To reach Macrocyclics in their new offices, please use the following:

    Beijing, China              Tokyo, Japan

    Mrs. Carrie SONG            Mr. Sebastien PAES

    +86 150 1146 1640                                    +81 90 2620 5448

    china@macrocyclics.com      japan@macrocyclics.com

    ---

    Seoul, South Korea          Limoges, France

    Mrs. Hye-Young PARK         Mr. Remy DUREAU

    +82 2 551 01 65                                     +33 6 46 42 45 65

    southkorea@macrocyclics.com france@macrocyclics.com

    ---

Macrocyclics specializes in the manufacture of customized chelating agents used in nuclear medicine and medical imaging. We also offer custom-made cGMP products for use in clinical trials, bioconjugation services, and consulting services that will help our customers select the proper isotopes for their particular needs.

Please visit http://www.macrocyclics.com for detailed information.

MORE ABOUT MACROCYCLICS

Macrocyclics is the global leader in high performance chelating agent technologies for medicine since 1995. Our team at Macrocyclics is dedicated to providing clients with both established and innovative chelating agents and services to meet the challenges of molecular imaging and nuclear medicine. www.macrocyclics.com

MORE ABOUT AREVA MED

AREVA Med is an AREVA subsidiary specializing in the development of innovative therapies to fight cancer. AREVA Med has developed new processes for producing high purity lead-212 ((212)Pb), a rare metal that is currently at the heart of promising nuclear medicine research. In 2011, AREVA Med acquired Macrocyclics, the global leader in high performance chelating agent technology. AREVA Med is also associated with world-class scientific partners, such as the National Cancer Institute (NCI), the University of Alabama at Birmingham (UAB), and the French National Institute of Health and Medical Research (Inserm). In 2012, AREVA Med and Roche entered a strategic alliance to create novel advanced alpha radioimmunotherapy treatments to target and kill certain very aggressive types of cancer cells. For more information: www.arevamed.com or www.targetedtrials.com. @AREVAmed

Macrocyclics
Garry Kiefer
T: +1 972 250 2248
F: +1 972 250 2245
info@macrocyclics.com

AREVA Med
Alison Tise
T: +1 301 841 1673
F: +1 240 235 0966
alison.tise@areva.com
@AREVAmed

SOURCE Macrocyclics, Inc.


Source: PR Newswire



comments powered by Disqus